Endovasc Creates Orphan Drug Trust; Financial Instrument Provides 50 Percent Tax Credit for Investors and Fast-Tracks Endovasc Through Phase III Human Clinical Trials MONTGOMERY, Texas, Sept. 24, 2002 (PRIMEZONE) -- Endovasc Ltd., Inc. (OTCBB:ENVC), a biotechnology company with two cardiovascular drugs approved for final FDA Phase III trials, announced today that...

Endovasc Ltd., Inc.: Biotech Company with the Only Angiogenesis Drug Approved for FDA Phase III Human Clinical Trials Creates a New Subsidiary MONTGOMERY, Texas, Sept. 17, 2002 (PRIMEZONE) -- Endovasc Ltd., Inc. (OTCBB:ENVC) announced today that in accordance with its new business model, the company has established a new subsidiary,...